Overview

Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients

Status:
Completed
Trial end date:
2018-10-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to ascertain whether Arotinolol Hydrochloride reduces mortality and cardiovascular events in chronic kidney disease stage 5 patients with hypertension.
Phase:
Phase 4
Details
Lead Sponsor:
Sumitomo Pharmaceutical (Suzhou) Co., Ltd.
Treatments:
Antihypertensive Agents
Arotinolol